Effectiveness of a 3-month Individual Reminiscence Therapy Program in Older Adults With Alzheimer… (NCT06812442) | Clinical Trial Compass
CompletedNot Applicable
Effectiveness of a 3-month Individual Reminiscence Therapy Program in Older Adults With Alzheimer's Disease
Portugal40 participantsStarted 2025-02-01
Plain-language summary
This research aims to evaluate the effectiveness of individual Reminiscence Therapy (RT) program, using a simple reminiscence format, to improve the overall cognitive function, mood, and quality of life (QoL) of older adults with mild to moderate Alzheimer's disease attending social care and support services. A multicentre randomised controlled trial (RCT) is proposed in Portugal with repeated measures (pre-intervention, and post-intervention). Intervention group will hold 26 individual RT sessions, twice a week for 13 weeks. Control group participants will maintain their treatment as usual. Make a subsample analysis of the main clinical diagnoses, and compare the results of sample and subsample with a previous study that had the same intervention protocol.
Who can participate
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 65 years or older.
* Receiving care and support services for at least three months.
* Diagnosis of probable Alzheimer's disease according to Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth edition text revision criteria.
* Intact communication skills.
* Native Portuguese speaking.
* Signed informed consent by the participant.
* Mini Mental State Examination (MMSE) score between 10 and 24 points
Exclusion Criteria:
* Severe sensory and physical limitations.
* Acute or serious illness precluding participation in the RT sessions.
* Evidence of aggressive and disruptive behaviour, as observed by staff at the facility.
* Starting neuroleptics or antipsychotics within two months of recruitment.
* No literacy (educational level).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Cognitive functioning evaluated through Mini-Mental State Examination (MMSE)
Timeframe: baseline
2
Change in cognitive functioning evaluated through MMSE
Timeframe: 13 weeks after the beginning of the intervention